InflaRx Reports Second Quarter 2023 Financial Results & Oper

10.08.2023 - • Quarter highlighted by the Emergency Use Authorization (EUA) and commercial launch of Gohibic (vilobelimab) in the United States • Oral C5aR inhibitor INF904 progressing in single ascending dose (SAD) and multiple ascending ...

Related Keywords

United States , Germany , Munich , Bayern , German , Katja Arnold , Thomas Taapken , Nielsc Riedemann , Laurie Doyle , Camilla Chong , Regina Lutz , Development Of Vilobelimab , European Medicines Agency , Global Medical Affairs Therapy Area Head , Exchange Commission , Drug Administration , Kyowa Kirin Corporation , Inflarx Pharmaceuticals Inc , Development Expenses , Mc Services , Chief Medical , Chief Executive Officer , Chief Medical Officer , Vice President , Global Medical Affairs , Therapy Area Head , Biologics License Application , European Committee , Medicinal Products , Human Use , Marketing Authorization Application , Pyoderma Gangrenosum , Low Molecular Weight , Cutaneous Squamous Cell Carcinoma , Criteria In Solid , Chief Financial Officer , Administrative Expenses , Marketing Expenses , Financial Result , Cash Used , Annual Report , Condensed Consolidated Statements , Comprehensive Loss , Comprehensive Income , Financial Position , Shareholder Equity , Cash Flows , Inflarx Pharmaceuticals , Ann Arbor , German Federal Government , Inflarx ,